1487 related articles for article (PubMed ID: 29042392)
1. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
[TBL] [Abstract][Full Text] [Related]
2. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
Packer M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Sattar N; Brueckmann M; Jamal W; Cotton D; Iwata T; Zannad F;
J Am Coll Cardiol; 2021 Mar; 77(11):1381-1392. PubMed ID: 33736819
[TBL] [Abstract][Full Text] [Related]
4. The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial.
Larsen EL; Cejvanovic V; Kjær LK; Vilsbøll T; Knop FK; Rungby J; Poulsen HE
BMJ Open; 2017 May; 7(5):e014728. PubMed ID: 28490557
[TBL] [Abstract][Full Text] [Related]
5. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Lytvyn Y; Bjornstad P; Udell JA; Lovshin JA; Cherney DZI
Circulation; 2017 Oct; 136(17):1643-1658. PubMed ID: 29061576
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.
Yabe D; Shiki K; Suzaki K; Meinicke T; Kotobuki Y; Nishida K; Clark D; Yasui A; Seino Y
BMJ Open; 2021 Apr; 11(4):e045844. PubMed ID: 33827843
[TBL] [Abstract][Full Text] [Related]
8. Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial.
Raven LM; Muir CA; Kessler Iglesias C; Bart NK; Muthiah K; Kotlyar E; Macdonald P; Hayward CS; Jabbour A; Greenfield JR
BMJ Open; 2023 Mar; 13(3):e069641. PubMed ID: 36990488
[TBL] [Abstract][Full Text] [Related]
9. Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).
Schulze PC; Bogoviku J; Westphal J; Aftanski P; Haertel F; Grund S; von Haehling S; Schumacher U; Möbius-Winkler S; Busch M
Circulation; 2022 Jul; 146(4):289-298. PubMed ID: 35766022
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.
Griffin M; Rao VS; Ivey-Miranda J; Fleming J; Mahoney D; Maulion C; Suda N; Siwakoti K; Ahmad T; Jacoby D; Riello R; Bellumkonda L; Cox Z; Collins S; Jeon S; Turner JM; Wilson FP; Butler J; Inzucchi SE; Testani JM
Circulation; 2020 Sep; 142(11):1028-1039. PubMed ID: 32410463
[TBL] [Abstract][Full Text] [Related]
11. Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study.
Brown AJM; Lang C; McCrimmon R; Struthers A
BMC Cardiovasc Disord; 2017 Aug; 17(1):229. PubMed ID: 28835229
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
Levin A; Perkovic V; Wheeler DC; Hantel S; George JT; von Eynatten M; Koitka-Weber A; Wanner C;
Clin J Am Soc Nephrol; 2020 Oct; 15(10):1433-1444. PubMed ID: 32994159
[TBL] [Abstract][Full Text] [Related]
13. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Jensen J; Omar M; Kistorp C; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Malik ME; Fosbøl EL; Bruun NE; Forman JL; Jensen LT; Møller JE; Schou M
Lancet Diabetes Endocrinol; 2021 Feb; 9(2):106-116. PubMed ID: 33357505
[TBL] [Abstract][Full Text] [Related]
14. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
Scheen AJ
Diabetes Metab; 2016 Sep; 42(4):224-33. PubMed ID: 27291329
[TBL] [Abstract][Full Text] [Related]
15. Similarities and distinctions between acetazolamide and sodium-glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE.
Packer M; Butler J
Eur J Heart Fail; 2023 Sep; 25(9):1537-1543. PubMed ID: 37403655
[TBL] [Abstract][Full Text] [Related]
16. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
17. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
Trujillo JM; Nuffer WA
Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030
[TBL] [Abstract][Full Text] [Related]
18. Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
Waijer SW; Xie D; Inzucchi SE; Zinman B; Koitka-Weber A; Mattheus M; von Eynatten M; Inker LA; Wanner C; Heerspink HJL
J Am Heart Assoc; 2020 Sep; 9(18):e016976. PubMed ID: 32893717
[TBL] [Abstract][Full Text] [Related]
19. Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial).
Jürgens M; Schou M; Hasbak P; Kjær A; Wolsk E; Zerahn B; Wiberg M; Brandt NH; Gæde PH; Rossing P; Faber J; Inzucchi S; Gustafsson F; Kistorp CM
BMJ Open; 2019 Nov; 9(11):e029098. PubMed ID: 31780586
[TBL] [Abstract][Full Text] [Related]
20. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]